Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 2 days agoScore70
Body · original
NATALEE 6-year OS analysis shows modest (early…given what we just saw in NSABP42…) improvement in OS.
IDFS benefit persists over time. #ESMO26 @OncoAlert
502 views · 8 likes · 5 reposts · 0 replies
Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgSource: Stephanie Graff, MD, FACP, FASCO · x.com